Gland Pharma Limited
GLAND
Rank in Stocks
#3270
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Share Price
$32.70
Market Cap
$5.40B
Change (1 day)
-1.88%
Change (1 year)
49.71%
Country
IN
Trade Gland Pharma Limited (GLAND)
Category
Healthcare
Earnings for Gland Pharma Limited (GLAND)
Earnings in Jun 2026 TTM: $175.12M
According to Gland Pharma Limited latest financial reports the company's current earnings are $175.12M. In 2024 the company made an earning of $135.82M, an increase over its 2023 earnings that were of $128.32M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Gland Pharma Limited from 2017 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $175.12M | 40.94% |
| 2025 | $124.25M | -8.52% |
| 2024 | $135.82M | 5.84% |
| 2023 | $128.32M | -39.82% |
| 2022 | $213.22M | 16.94% |
| 2021 | $182.34M | 38.35% |
| 2020 | $131.79M | 33.35% |
| 2019 | $98.83M | 28.32% |
| 2018 | $77.02M | -13.59% |
| 2017 | $89.13M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 907.63% |
IN
|
